Clinical readout

AusperBio's AHB-137 keeps hepatitis B functional cure 15 months off therapy

In long-term follow-up of phase 2 responders, every participant reaching the 15-month mark after stopping all hepatitis B treatment remained functionally cured, nine pretreated and six treatment-naive. No clinical relapse or new safety signal was seen. The antisense drug is in phase 3 in China.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call